ODAC voted 7–1 (one abstention) that capivasertib plus abiraterone and ADT shows a favorable benefit–risk profile for ...
In today's Pharmaceutical Executive Daily, the FDA's Oncologic Drugs Advisory Committee votes a favorable benefit-risk ...
In a conversation with Pharmaceutical Executive, Jeff Golfman, founder and president of Send 123, discusses how and why ...
FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene ...
Building manufacturer partnerships depends on trust, data-driven insights, and integrated teams spanning market access, ...
Synchronizing sales and marketing around a unified, customer-centric approach is essential for pharmaceutical companies ...
In the final part of his interview, Jeff Golfman discusses how data-driven supply chain mapping and collaborative procurement ...
Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability. Will Shrank, CEO ...
GLP-1 agonists have become the dominant spend catalyst, with class spending ~$132B and growth contribution approaching ...
While advances in cell & gene therapy continue to show promise for creating new treatments, this sector of the industry still ...
Sydni Johnston, Associate Director at Cardinal Health Sonexus™ Access and Patient Support, explains how manufacturers can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results